1
|
Farley KA, Stack KM, Shuster DL, Horgan BHN, Hurowitz JA, Tarnas JD, Simon JI, Sun VZ, Scheller EL, Moore KR, McLennan SM, Vasconcelos PM, Wiens RC, Treiman AH, Mayhew LE, Beyssac O, Kizovski TV, Tosca NJ, Williford KH, Crumpler LS, Beegle LW, Bell JF, Ehlmann BL, Liu Y, Maki JN, Schmidt ME, Allwood AC, Amundsen HEF, Bhartia R, Bosak T, Brown AJ, Clark BC, Cousin A, Forni O, Gabriel TSJ, Goreva Y, Gupta S, Hamran SE, Herd CDK, Hickman-Lewis K, Johnson JR, Kah LC, Kelemen PB, Kinch KB, Mandon L, Mangold N, Quantin-Nataf C, Rice MS, Russell PS, Sharma S, Siljeström S, Steele A, Sullivan R, Wadhwa M, Weiss BP, Williams AJ, Wogsland BV, Willis PA, Acosta-Maeda TA, Beck P, Benzerara K, Bernard S, Burton AS, Cardarelli EL, Chide B, Clavé E, Cloutis EA, Cohen BA, Czaja AD, Debaille V, Dehouck E, Fairén AG, Flannery DT, Fleron SZ, Fouchet T, Frydenvang J, Garczynski BJ, Gibbons EF, Hausrath EM, Hayes AG, Henneke J, Jørgensen JL, Kelly EM, Lasue J, Le Mouélic S, Madariaga JM, Maurice S, Merusi M, Meslin PY, Milkovich SM, Million CC, Moeller RC, Núñez JI, Ollila AM, Paar G, Paige DA, Pedersen DAK, Pilleri P, Pilorget C, Pinet PC, Rice JW, Royer C, Sautter V, Schulte M, Sephton MA, Sharma SK, Sholes SF, Spanovich N, St Clair M, Tate CD, Uckert K, VanBommel SJ, Yanchilina AG, Zorzano MP. Aqueously altered igneous rocks sampled on the floor of Jezero crater, Mars. Science 2022; 377:eabo2196. [PMID: 36007009 DOI: 10.1126/science.abo2196] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The Perseverance rover landed in Jezero crater, Mars, to investigate ancient lake and river deposits. We report observations of the crater floor, below the crater's sedimentary delta, finding the floor consists of igneous rocks altered by water. The lowest exposed unit, informally named Séítah, is a coarsely crystalline olivine-rich rock, which accumulated at the base of a magma body. Fe-Mg carbonates along grain boundaries indicate reactions with CO2-rich water, under water-poor conditions. Overlying Séítah is a unit informally named Máaz, which we interpret as lava flows or the chemical complement to Séítah in a layered igneous body. Voids in these rocks contain sulfates and perchlorates, likely introduced by later near-surface brine evaporation. Core samples of these rocks were stored aboard Perseverance for potential return to Earth.
Collapse
Affiliation(s)
- K A Farley
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - K M Stack
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - D L Shuster
- Department of Earth and Planetary Science, University of California, Berkeley, Berkeley, CA 94720, USA
| | - B H N Horgan
- Department of Earth, Atmospheric, and Planetary Sciences, Purdue University, West Lafayette, IN 47907, USA
| | - J A Hurowitz
- Department of Geosciences, Stony Brook University, Stony Brook, NY 11794, USA
| | - J D Tarnas
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - J I Simon
- Center for Isotope Cosmochemistry and Geochronology, Astromaterials Research and Exploration Science Division, NASA Johnson Space Center, Houston, TX 77058, USA
| | - V Z Sun
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - E L Scheller
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - K R Moore
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - S M McLennan
- Department of Geosciences, Stony Brook University, Stony Brook, NY 11794, USA
| | - P M Vasconcelos
- School of Earth and Environmental Sciences, University of Queensland, Brisbane, QLD 4072, Australia
| | - R C Wiens
- Planetary Exploration Team, Los Alamos National Laboratory, Los Alamos, NM 87545, USA
| | - A H Treiman
- Lunar and Planetary Institute, Universities Space Research Association, Houston, TX 77058, USA
| | - L E Mayhew
- Department of Geological Sciences, University of Colorado, Boulder, Boulder, CO 80309, USA
| | - O Beyssac
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Centre National de la Recherche Scientifique, Sorbonne Université, Muséum National d'Histoire Naturelle, 75005 Paris, France
| | - T V Kizovski
- Department of Earth Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada
| | - N J Tosca
- Department of Earth Sciences, University of Cambridge, Cambridge CB2 3EQ, UK
| | - K H Williford
- Blue Marble Space Institute of Science, Seattle, WA 98104, USA
| | - L S Crumpler
- New Mexico Museum of Natural History and Science, Albuquerque, NM 8710, USA
| | - L W Beegle
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - J F Bell
- School of Earth and Space Exploration, Arizona State University, Tempe, AZ 85287, USA
| | - B L Ehlmann
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - Y Liu
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - J N Maki
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - M E Schmidt
- Department of Earth Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada
| | - A C Allwood
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - H E F Amundsen
- Center for Space Sensors and Systems, University of Oslo, 2007 Kjeller, Norway
| | - R Bhartia
- Photon Systems Inc., Covina, CA 91725, USA
| | - T Bosak
- Department of Earth, Atmospheric and Planetary Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - A J Brown
- Plancius Research, Severna Park, MD 21146, USA
| | - B C Clark
- Space Science Institute, Boulder, CO 80301, USA
| | - A Cousin
- Institut de Recherche en Astrophysique et Planétologie, Université de Toulouse 3 Paul Sabatier, Centre National de la Recherche Scientifique, Centre National d'Etude Spatiale, 31400 Toulouse, France
| | - O Forni
- Institut de Recherche en Astrophysique et Planétologie, Université de Toulouse 3 Paul Sabatier, Centre National de la Recherche Scientifique, Centre National d'Etude Spatiale, 31400 Toulouse, France
| | - T S J Gabriel
- Astrogeology Science Center, US Geological Survey, Flagstaff, AZ 86001, USA
| | - Y Goreva
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - S Gupta
- Department of Earth Sciences and Engineering, Imperial College London, London SW7 2AZ, UK
| | - S-E Hamran
- Center for Space Sensors and Systems, University of Oslo, 2007 Kjeller, Norway
| | - C D K Herd
- Department of Earth and Atmospheric Sciences, University of Alberta, Edmonton, AB T6G 2E3, Canada
| | - K Hickman-Lewis
- Department of Earth Sciences, The Natural History Museum, London SW7 5BD, UK.,Dipartimento di Scienze Biologiche, Geologiche e Ambientali, Università di Bologna, 40126 Bologna, Italy
| | - J R Johnson
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - L C Kah
- Department of Earth and Planetary Sciences, University of Tennessee, Knoxville, TN 37996, USA
| | - P B Kelemen
- Department of Earth and Environmental Sciences, Lamont Doherty Earth Observatory of Columbia University, Palisades, NY 10964, USA
| | - K B Kinch
- Niels Bohr Institute, University of Copenhagen, 1350 Copenhagen, Denmark
| | - L Mandon
- Laboratoire d'Etudes Spatiales et d'Instrumentation en Astrophysique, Observatoire de Paris, Centre National de la Recherche Scientifique, Sorbonne Université, Université Paris Diderot, 92195 Meudon, France
| | - N Mangold
- Laboratoire de Planétologie et Géosciences, Centre National de la Recherche Scientifique, Nantes Université, Université Angers, 44000 Nantes, France
| | - C Quantin-Nataf
- Laboratoire de Géologie de Lyon: Terre, Université de Lyon, Université Claude Bernard Lyon1, Ecole Normale Supérieure de Lyon, Université Jean Monnet Saint Etienne, Centre National de la Recherche Scientifique, 69622 Villeurbanne, France
| | - M S Rice
- Department of Geology, Western Washington University, Bellingham, WA 98225 USA
| | - P S Russell
- Department of Earth, Planetary, and Space Sciences, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - S Sharma
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - S Siljeström
- Department of Methodology, Textiles and Medical Technology, Research Institutes of Sweden, 11486 Stockholm, Sweden
| | - A Steele
- Earth and Planetary Laboratory, Carnegie Science, Washington, DC 20015, USA
| | - R Sullivan
- Cornell Center for Astrophysics and Planetary Science, Cornell University, Ithaca, NY 14853, USA
| | - M Wadhwa
- School of Earth and Space Exploration, Arizona State University, Tempe, AZ 85287, USA
| | - B P Weiss
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA.,Department of Earth, Atmospheric and Planetary Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - A J Williams
- Department of Geological Sciences, University of Florida, Gainesville, FL 32611, USA
| | - B V Wogsland
- Department of Earth and Planetary Sciences, University of Tennessee, Knoxville, TN 37996, USA
| | - P A Willis
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - T A Acosta-Maeda
- Hawai'i Institute of Geophysics and Planetology, University of Hawai'i at Mānoa, Honolulu, HI 96822, USA
| | - P Beck
- Institut de Planétologie et Astrophysique de Grenoble, Centre National de la Recherche Scientifique, Université Grenoble Alpes, 38000 Grenoble, France
| | - K Benzerara
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Centre National de la Recherche Scientifique, Sorbonne Université, Muséum National d'Histoire Naturelle, 75005 Paris, France
| | - S Bernard
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Centre National de la Recherche Scientifique, Sorbonne Université, Muséum National d'Histoire Naturelle, 75005 Paris, France
| | - A S Burton
- NASA Johnson Space Center, Houston, TX 77058, USA
| | - E L Cardarelli
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - B Chide
- Planetary Exploration Team, Los Alamos National Laboratory, Los Alamos, NM 87545, USA
| | - E Clavé
- Centre Lasers Intenses et Applications, Centre National de la Recherche Scientifique, Commissariat à l'Energie Atomique, Université de Bordeaux, 33400 Bordeaux, France
| | - E A Cloutis
- Centre for Terrestrial and Planetary Exploration, University of Winnipeg, Winnipeg, MB R3B 2E9, Canada
| | - B A Cohen
- NASA Goddard Space Flight Center, Greenbelt, MD 20771, USA
| | - A D Czaja
- Department of Geology, University of Cincinnati, Cincinnati, OH 45221, USA
| | - V Debaille
- Laboratoire G-Time, Université Libre de Bruxelles, 1050 Brussels, Belgium
| | - E Dehouck
- Laboratoire de Géologie de Lyon: Terre, Université de Lyon, Université Claude Bernard Lyon1, Ecole Normale Supérieure de Lyon, Université Jean Monnet Saint Etienne, Centre National de la Recherche Scientifique, 69622 Villeurbanne, France
| | - A G Fairén
- Centro de Astrobiología, Consejo Superior de Investigaciones Científicas-Instituto Nacional de Técnica Aeroespacial, 28850 Madrid, Spain.,Department of Astronomy, Cornell University, Ithaca, NY 14853, USA
| | - D T Flannery
- School of Earth and Atmospheric Sciences, Queensland University of Technology, Brisbane, QLD 4001, Australia
| | - S Z Fleron
- Department of Geosciences and Natural Resource Management, University of Copenhagen, 1350 Copenhagen, Denmark
| | - T Fouchet
- Laboratoire d'Etudes Spatiales et d'Instrumentation en Astrophysique, Observatoire de Paris, Centre National de la Recherche Scientifique, Sorbonne Université, Université Paris Diderot, 92195 Meudon, France
| | - J Frydenvang
- Globe Institute, University of Copenhagen, 1350 Copenhagen, Denmark
| | - B J Garczynski
- Department of Earth, Atmospheric, and Planetary Sciences, Purdue University, West Lafayette, IN 47907, USA
| | - E F Gibbons
- Department of Earth and Planetary Sciences, McGill University, Montreal, QC H3A 0E8, Canada
| | - E M Hausrath
- Department of Geoscience, University of Nevada, Las Vegas, Las Vegas, NV 89154, USA
| | - A G Hayes
- Department of Astronomy, Cornell University, Ithaca, NY 14853, USA
| | - J Henneke
- National Space Institute, Technical University of Denmark, 2800 Kongens Lyngby, Denmark
| | - J L Jørgensen
- National Space Institute, Technical University of Denmark, 2800 Kongens Lyngby, Denmark
| | - E M Kelly
- Hawai'i Institute of Geophysics and Planetology, University of Hawai'i at Mānoa, Honolulu, HI 96822, USA
| | - J Lasue
- Institut de Recherche en Astrophysique et Planétologie, Université de Toulouse 3 Paul Sabatier, Centre National de la Recherche Scientifique, Centre National d'Etude Spatiale, 31400 Toulouse, France
| | - S Le Mouélic
- Laboratoire de Planétologie et Géosciences, Centre National de la Recherche Scientifique, Nantes Université, Université Angers, 44000 Nantes, France
| | - J M Madariaga
- Department of Analytical Chemistry, University of the Basque Country, 48940 Leioa, Spain
| | - S Maurice
- Institut de Recherche en Astrophysique et Planétologie, Université de Toulouse 3 Paul Sabatier, Centre National de la Recherche Scientifique, Centre National d'Etude Spatiale, 31400 Toulouse, France
| | - M Merusi
- Niels Bohr Institute, University of Copenhagen, 1350 Copenhagen, Denmark
| | - P-Y Meslin
- Institut de Recherche en Astrophysique et Planétologie, Université de Toulouse 3 Paul Sabatier, Centre National de la Recherche Scientifique, Centre National d'Etude Spatiale, 31400 Toulouse, France
| | - S M Milkovich
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | | | - R C Moeller
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - J I Núñez
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - A M Ollila
- Los Alamos National Laboratory, Los Alamos, NM 87545 USA
| | - G Paar
- Institute for Information and Communication Technologies, Joanneum Research, 8010 Graz, Austria
| | - D A Paige
- Department of Earth, Planetary, and Space Sciences, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - D A K Pedersen
- National Space Institute, Technical University of Denmark, 2800 Kongens Lyngby, Denmark
| | - P Pilleri
- Institut de Recherche en Astrophysique et Planétologie, Université de Toulouse 3 Paul Sabatier, Centre National de la Recherche Scientifique, Centre National d'Etude Spatiale, 31400 Toulouse, France
| | - C Pilorget
- Institut d'Astrophysique Spatiale, Université Paris-Saclay, 91405 Orsay, France.,Institut Universitaire de France, Paris, France
| | - P C Pinet
- Institut de Recherche en Astrophysique et Planétologie, Université de Toulouse 3 Paul Sabatier, Centre National de la Recherche Scientifique, Centre National d'Etude Spatiale, 31400 Toulouse, France
| | - J W Rice
- School of Earth and Space Exploration, Arizona State University, Tempe, AZ 85287, USA
| | - C Royer
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Centre National de la Recherche Scientifique, Sorbonne Université, Muséum National d'Histoire Naturelle, 75005 Paris, France
| | - V Sautter
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Centre National de la Recherche Scientifique, Sorbonne Université, Muséum National d'Histoire Naturelle, 75005 Paris, France
| | - M Schulte
- Mars Exploration Program, Planetary Science Division, NASA Headquarters, Washington, DC 20546, USA
| | - M A Sephton
- Department of Earth Sciences and Engineering, Imperial College London, London SW7 2AZ, UK
| | - S K Sharma
- Hawai'i Institute of Geophysics and Planetology, University of Hawai'i at Mānoa, Honolulu, HI 96822, USA
| | - S F Sholes
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - N Spanovich
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - M St Clair
- Million Concepts, Louisville, KY 40204, USA
| | - C D Tate
- Department of Astronomy, Cornell University, Ithaca, NY 14853, USA
| | - K Uckert
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - S J VanBommel
- McDonnell Center for the Space Sciences and Department of Earth and Planetary Sciences, Washington University in St. Louis, St. Louis, MO 63130, USA
| | | | - M-P Zorzano
- Department of Astronomy, Cornell University, Ithaca, NY 14853, USA
| |
Collapse
|
2
|
Liu Y, Tice MM, Schmidt ME, Treiman AH, Kizovski TV, Hurowitz JA, Allwood AC, Henneke J, Pedersen DAK, VanBommel SJ, Jones MWM, Knight AL, Orenstein BJ, Clark BC, Elam WT, Heirwegh CM, Barber T, Beegle LW, Benzerara K, Bernard S, Beyssac O, Bosak T, Brown AJ, Cardarelli EL, Catling DC, Christian JR, Cloutis EA, Cohen BA, Davidoff S, Fairén AG, Farley KA, Flannery DT, Galvin A, Grotzinger JP, Gupta S, Hall J, Herd CDK, Hickman-Lewis K, Hodyss RP, Horgan BHN, Johnson JR, Jørgensen JL, Kah LC, Maki JN, Mandon L, Mangold N, McCubbin FM, McLennan SM, Moore K, Nachon M, Nemere P, Nothdurft LD, Núñez JI, O'Neil L, Quantin-Nataf CM, Sautter V, Shuster DL, Siebach KL, Simon JI, Sinclair KP, Stack KM, Steele A, Tarnas JD, Tosca NJ, Uckert K, Udry A, Wade LA, Weiss BP, Wiens RC, Williford KH, Zorzano MP. An olivine cumulate outcrop on the floor of Jezero crater, Mars. Science 2022; 377:1513-1519. [PMID: 36007094 DOI: 10.1126/science.abo2756] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
The geological units on the floor of Jezero crater, Mars, are part of a wider regional stratigraphy of olivine-rich rocks, which extends well beyond the crater. We investigate the petrology of olivine and carbonate-bearing rocks of the Séítah formation in the floor of Jezero. Using multispectral images and x-ray fluorescence data, acquired by the Perseverance rover, we performed a petrographic analysis of the Bastide and Brac outcrops within this unit. We find that these outcrops are composed of igneous rock, moderately altered by aqueous fluid. The igneous rocks are mainly made of coarse-grained olivine, similar to some Martian meteorites. We interpret them as an olivine cumulate, formed by settling and enrichment of olivine through multi-stage cooling of a thick magma body.
Collapse
Affiliation(s)
- Y Liu
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - M M Tice
- Department of Geology and Geophysics, Texas A&M University, College Station, TX 77843, USA
| | - M E Schmidt
- Department of Earth Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada
| | - A H Treiman
- Lunar and Planetary Institute, Universities Space Research Association, Houston TX 77058, USA
| | - T V Kizovski
- Department of Earth Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada
| | - J A Hurowitz
- Department of Geosciences, Stony Brook University, Stony Brook, NY 11794, USA
| | - A C Allwood
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - J Henneke
- Department of Space, Measurement and Instrumentation, Technical University of Denmark,, Lyngby, Denmark
| | - D A K Pedersen
- Department of Space, Measurement and Instrumentation, Technical University of Denmark,, Lyngby, Denmark
| | - S J VanBommel
- McDonnell Center for the Space Sciences, Department of Earth and Planetary Sciences, Washington University in St. Louis, St. Louis, MO 63130, USA
| | - M W M Jones
- Central Analytical Research Facility, and School of Chemistry and Physics, Queensland University of Technology, Brisbane, QLD 4000, Australia
| | - A L Knight
- McDonnell Center for the Space Sciences, Department of Earth and Planetary Sciences, Washington University in St. Louis, St. Louis, MO 63130, USA
| | - B J Orenstein
- School of Earth and Atmospheric Sciences, Queensland University of Technology, Brisbane, QLD 4000, Australia
| | - B C Clark
- Space Science Institute, Boulder, CO 80301, USA
| | - W T Elam
- Applied Physics Lab and Department of Earth and Space Sciences, University of Washington, Seattle, WA 98052, USA
| | - C M Heirwegh
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - T Barber
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - L W Beegle
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - K Benzerara
- Institut de Minéralogie, Physique des Matériaux et Cosmochimie, Centre National de la Recherche Scientifique (CNRS), Muséum National d'Histoire Naturelle, Sorbonne Université, Paris 75005, France
| | - S Bernard
- Institut de Minéralogie, Physique des Matériaux et Cosmochimie, Centre National de la Recherche Scientifique (CNRS), Muséum National d'Histoire Naturelle, Sorbonne Université, Paris 75005, France
| | - O Beyssac
- Institut de Minéralogie, Physique des Matériaux et Cosmochimie, Centre National de la Recherche Scientifique (CNRS), Muséum National d'Histoire Naturelle, Sorbonne Université, Paris 75005, France
| | - T Bosak
- Department of Earth, Atmospheric and Planetary Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | | | - E L Cardarelli
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - D C Catling
- Department of Earth and Space Sciences, University of Washington, Seattle WA 98195, USA
| | - J R Christian
- McDonnell Center for the Space Sciences, Department of Earth and Planetary Sciences, Washington University in St. Louis, St. Louis, MO 63130, USA
| | - E A Cloutis
- Department of Geography, University of Winnipeg, Winnipeg, Manitoba R3B 2E9, Canada
| | - B A Cohen
- NASA Goddard Space Flight Center, Greenbelt, MD 20771, USA
| | - S Davidoff
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - A G Fairén
- Centro de Astrobiología, Consejo Superior de Investigaciones Cientificas - Instituto Nacional de Tecnica Aeroespacial, Madrid 28850, Spain.,Dept. of Astronomy, Cornell University, Ithaca, NY 14853, USA
| | - K A Farley
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - D T Flannery
- School of Earth and Atmospheric Sciences, Queensland University of Technology, Brisbane, QLD 4000, Australia
| | - A Galvin
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - J P Grotzinger
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - S Gupta
- Department of Earth Science and Engineering, Imperial College London, London SW7 2AZ, UK
| | - J Hall
- Department of Earth, Atmospheric and Planetary Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - C D K Herd
- Department of Earth and Atmospheric Sciences, University of Alberta, Edmonton, Alberta T6G 2E3, Canada
| | - K Hickman-Lewis
- Department of Earth Sciences, The Natural History Museum, South Kensington, London, SW7 5BD, UK.,Dipartimento di Scienze Biologiche, Geologiche e Ambientali, Università di Bologna, via Zamboni 67, I-40126 Bologna, Italy
| | - R P Hodyss
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - B H N Horgan
- Department of Earth, Atmospheric, and Planetary Sciences, Purdue University, West Lafayette, IN 47907, USA
| | - J R Johnson
- Johns Hopkins University Applied Physics Laboratory Laurel, MD 20723, USA
| | - J L Jørgensen
- Department of Space, Measurement and Instrumentation, Technical University of Denmark,, Lyngby, Denmark
| | - L C Kah
- Department of Earth and Planetary Sciences, University of Tennessee, Knoxville TN 37996, USA
| | - J N Maki
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - L Mandon
- Laboratoire d'Etudes Spatiales et d'Instrumentation en Astrophysique, Observatoire de Paris-Université Paris Sciences et Lettres, CNRS, Sorbonne Université, Université de Paris Cité, Meudon 92190, France
| | - N Mangold
- Laboratoire Planetologie et Geosciences, Centre National de Recherches Scientifiques, Universite Nantes, Universite Angers, Unite Mixte de Recherche 6112, Nantes 44322, France
| | - F M McCubbin
- NASA Johnson Space Center, Houston, TX 77058, USA
| | - S M McLennan
- Department of Geosciences, Stony Brook University, Stony Brook, NY 11794, USA
| | - K Moore
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - M Nachon
- Department of Geology and Geophysics, Texas A&M University, College Station, TX 77843, USA
| | - P Nemere
- School of Earth and Atmospheric Sciences, Queensland University of Technology, Brisbane, QLD 4000, Australia
| | - L D Nothdurft
- School of Earth and Atmospheric Sciences, Queensland University of Technology, Brisbane, QLD 4000, Australia
| | - J I Núñez
- Johns Hopkins University Applied Physics Laboratory Laurel, MD 20723, USA
| | - L O'Neil
- Applied Physics Lab and Department of Earth and Space Sciences, University of Washington, Seattle, WA 98052, USA
| | - C M Quantin-Nataf
- Laboratoire de Geologie de Lyon-Terre Planetes Environnement, Univ Lyon, Universite Claude Bernard Lyon 1, Ecole Normale Superieure Lyon, Centre National de Recherches Scientifiques, 69622 Villeurbanne, France
| | - V Sautter
- Institut de Minéralogie, Physique des Matériaux et Cosmochimie, Centre National de la Recherche Scientifique (CNRS), Muséum National d'Histoire Naturelle, Sorbonne Université, Paris 75005, France
| | - D L Shuster
- Dept. Earth and Planetary Science, University of California, Berkeley, CA 94720, USA
| | - K L Siebach
- Department of Earth, Environmental, and Planetary Sciences, Rice University, Houston, TX 77005, USA
| | - J I Simon
- NASA Johnson Space Center, Houston, TX 77058, USA
| | - K P Sinclair
- Applied Physics Lab and Department of Earth and Space Sciences, University of Washington, Seattle, WA 98052, USA
| | - K M Stack
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - A Steele
- Earth and Planets Laboratory, Carnegie Institution for Science, Washington, DC 20015, USA
| | - J D Tarnas
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - N J Tosca
- Department of Earth Sciences, University of Cambridge, Cambridge, CB2 3EQ, UK
| | - K Uckert
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - A Udry
- Department of Geosciences University of Nevada Las Vegas, Las Vegas, NV 89154, USA
| | - L A Wade
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - B P Weiss
- Department of Earth, Atmospheric and Planetary Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - R C Wiens
- Los Alamos National Laboratory, Los Alamos, NM 87545, USA
| | - K H Williford
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA.,Blue Marble Space Institute of Science, 600 1st Ave. Seattle, WA 98104, USA
| | - M-P Zorzano
- Centro de Astrobiología, Consejo Superior de Investigaciones Cientificas - Instituto Nacional de Tecnica Aeroespacial, Madrid 28850, Spain
| |
Collapse
|
3
|
Mangold N, Gupta S, Gasnault O, Dromart G, Tarnas JD, Sholes SF, Horgan B, Quantin-Nataf C, Brown AJ, Le Mouélic S, Yingst RA, Bell JF, Beyssac O, Bosak T, Calef F, Ehlmann BL, Farley KA, Grotzinger JP, Hickman-Lewis K, Holm-Alwmark S, Kah LC, Martinez-Frias J, McLennan SM, Maurice S, Nuñez JI, Ollila AM, Pilleri P, Rice JW, Rice M, Simon JI, Shuster DL, Stack KM, Sun VZ, Treiman AH, Weiss BP, Wiens RC, Williams AJ, Williams NR, Williford KH. Perseverance rover reveals an ancient delta-lake system and flood deposits at Jezero crater, Mars. Science 2021; 374:711-717. [PMID: 34618548 DOI: 10.1126/science.abl4051] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- N Mangold
- Laboratoire Planétologie et Géodynamique, Centre National de Recherches Scientifiques, Université Nantes, Université Angers, Unité Mixte de Recherche 6112, 44322 Nantes, France
| | - S Gupta
- Department of Earth Science and Engineering, Imperial College London, London SW7 2AZ, UK
| | - O Gasnault
- Institut de Recherche en Astrophysique et Planétologie, Université de Toulouse, Université Paul Sabatier, Centre National de Recherches Scientifiques, Observatoire Midi-Pyrénées, 31400 Toulouse, France
| | - G Dromart
- Laboratoire de Géologie de Lyon-Terre Planètes Environnement, Univ Lyon, Université Claude Bernard Lyon 1, Ecole Normale Supérieure Lyon, Centre National de Recherches Scientifiques, 69622 Villeurbanne, France
| | - J D Tarnas
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - S F Sholes
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - B Horgan
- Department of Earth, Atmospheric, and Planetary Sciences, Purdue University, West Lafayette, IN 47907, USA
| | - C Quantin-Nataf
- Laboratoire de Géologie de Lyon-Terre Planètes Environnement, Univ Lyon, Université Claude Bernard Lyon 1, Ecole Normale Supérieure Lyon, Centre National de Recherches Scientifiques, 69622 Villeurbanne, France
| | - A J Brown
- Plancius Research, Severna Park, MD 21146, USA
| | - S Le Mouélic
- Laboratoire Planétologie et Géodynamique, Centre National de Recherches Scientifiques, Université Nantes, Université Angers, Unité Mixte de Recherche 6112, 44322 Nantes, France
| | - R A Yingst
- Planetary Science Institute, Tucson, AZ 85719, USA
| | - J F Bell
- School of Earth and Space Exploration, Arizona State University, Tempe, AZ 85287, USA
| | - O Beyssac
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Unité Mixte de Recherche 7590, Centre National de Recherches Scientifiques, Sorbonne Université, Museum National d'Histoires Naturelles, 75005 Paris, France
| | - T Bosak
- Department of Earth, Atmospheric, and Planetary Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - F Calef
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - B L Ehlmann
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - K A Farley
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - J P Grotzinger
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - K Hickman-Lewis
- Department of Earth Sciences, The Natural History Museum, South Kensington, London SW7 5BD, UK.,Dipartimento di Scienze Biologiche, Geologiche e Ambientali, Università di Bologna, I-40126 Bologna, Italy
| | - S Holm-Alwmark
- Niels Bohr Institute, University of Copenhagen, 2100 Copenhagen, Denmark.,Department of Geology, Lund University, 22362 Lund, Sweden.,Natural History Museum of Denmark, University of Copenhagen, 1350 Copenhagen, Denmark
| | - L C Kah
- Department of Earth and Planetary Sciences, University of Tennessee, Knoxville, TN 37996, USA
| | - J Martinez-Frias
- Instituto de Geociencias, Consejo Superior de Investigaciones Cientificas, Universidad Complutense Madrid, 28040 Madrid, Spain
| | - S M McLennan
- Department of Geosciences, Stony Brook University, Stony Brook, NY 11794, USA
| | - S Maurice
- Institut de Recherche en Astrophysique et Planétologie, Université de Toulouse, Université Paul Sabatier, Centre National de Recherches Scientifiques, Observatoire Midi-Pyrénées, 31400 Toulouse, France
| | - J I Nuñez
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - A M Ollila
- Space and Planetary Exploration Team, Los Alamos National Laboratory, Los Alamos, NM 87545, USA
| | - P Pilleri
- Institut de Recherche en Astrophysique et Planétologie, Université de Toulouse, Université Paul Sabatier, Centre National de Recherches Scientifiques, Observatoire Midi-Pyrénées, 31400 Toulouse, France
| | - J W Rice
- School of Earth and Space Exploration, Arizona State University, Tempe, AZ 85287, USA
| | - M Rice
- Geology Department, College of Science and Engineering, Western Washington University, Bellingham, WA 98225, USA
| | - J I Simon
- Center for Isotope Cosmochemistry and Geochronology, Astromaterials Research and Exploration Science, NASA Johnson Space Center, Houston, TX 77058, USA
| | - D L Shuster
- Department of Earth and Planetary Science, University of California, Berkeley, CA 94720, USA
| | - K M Stack
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - V Z Sun
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - A H Treiman
- Lunar and Planetary Institute, Universities Space Research Association, Houston, TX 77058, USA
| | - B P Weiss
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA.,Department of Earth, Atmospheric, and Planetary Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - R C Wiens
- Space and Planetary Exploration Team, Los Alamos National Laboratory, Los Alamos, NM 87545, USA
| | - A J Williams
- Department of Geological Sciences, University of Florida, Gainesville, FL 32611, USA
| | - N R Williams
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - K H Williford
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA.,Blue Marble Space Institute of Science, Seattle, WA 98104, USA
| |
Collapse
|
4
|
Shuster DL, Pastino G, Cerneus D. Framework for the Design of Cannabis-Mediated Phase I Drug-Drug Interaction Studies. Curr Rev Clin Exp Pharmacol 2021; 17:18-25. [PMID: 34455952 DOI: 10.2174/2772432816666210813123716] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Revised: 04/22/2021] [Accepted: 06/11/2021] [Indexed: 12/12/2022]
Abstract
Cannabis has become legal in much of the United States similarly to many other countries, for either recreational or medical use. The use of cannabis products is rapidly increasing while the body of knowledge of its myriad of effects still lags. In vitro and clinical data show that cannabis' main constituents, delta-9-tetrahydrocannabinol and cannabidiol, can affect the pharmacokinetics (PK), safety and pharmacodynamics (PD) of other drugs. Within the context of clinical drug development, the widespread and frequent use of cannabis products has essentially created another special population; that is, the cannabis user. We propose that all clinical drug development programs include a Phase 1 study to assess the drug-drug interaction potential of cannabis as a precipitant on the PK, safety and if applicable, the PD of all new molecular entities (NMEs) in a combination of healthy adult subjects as well as frequent and infrequent cannabis users. This data should be required to inform drug labeling and aid health care providers in treating any patient, as cannabis has quickly become another common concomitant medication and cannabis users, a new special population.
Collapse
Affiliation(s)
| | - Gina Pastino
- PRA Health Sciences, Millcreek, UT. United States
| | - Dirk Cerneus
- PRA Health Sciences, Millcreek, UT. United States
| |
Collapse
|
5
|
Shuster DL, Shireman LM, Ma X, Shen DD, Flood Nichols SK, Ahmed MS, Clark S, Caritis S, Venkataramanan R, Haas DM, Quinney SK, Haneline LS, Tita AT, Manuck TA, Thummel KE, Brown LM, Ren Z, Brown Z, Easterling TR, Hebert MF. Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus. Clin Pharmacol Ther 2020; 107:1362-1372. [PMID: 31869430 DOI: 10.1002/cpt.1749] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Accepted: 10/23/2019] [Indexed: 12/16/2022]
Abstract
In gestational diabetes mellitus (GDM), women are unable to compensate for the increased insulin resistance during pregnancy. Data are limited regarding the pharmacodynamic effects of metformin and glyburide during pregnancy. This study characterized insulin sensitivity (SI), β-cell responsivity, and disposition index (DI) in women with GDM utilizing a mixed-meal tolerance test (MMTT) before and during treatment with glyburide monotherapy (GLY, n = 38), metformin monotherapy (MET, n = 34), or GLY and MET combination therapy (COMBO; n = 36). GLY significantly decreased dynamic β-cell responsivity (31%). MET and COMBO significantly increased SI (121% and 83%, respectively). Whereas GLY, MET, and COMBO improved DI, metformin (MET and COMBO) demonstrated a larger increase in DI (P = 0.05) and a larger decrease in MMTT peak glucose concentrations (P = 0.03) than subjects taking only GLY. Maximizing SI with MET followed by increasing β-cell responsivity with GLY or supplementing with insulin might be a more optimal strategy for GDM management than monotherapy.
Collapse
Affiliation(s)
- Diana L Shuster
- Clinical Pharmacology - Scientific Affairs, PRA Health Sciences, Lenexa, Kansas, USA
| | - Laura M Shireman
- Departments of Pharmaceutics, University of Washington, Seattle, Washington, USA
| | - Xiaosu Ma
- Global PK/PD & Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA
| | - Danny D Shen
- Departments of Pharmaceutics, University of Washington, Seattle, Washington, USA
| | - Shannon K Flood Nichols
- Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Madigan Army Medical Center, Tacoma, Washington, USA
| | - Mahmoud S Ahmed
- Department of Obstetrics & Gynecology, University of Texas Medical Branch in Galveston, Galveston, Texas, USA
| | - Shannon Clark
- Department of Obstetrics & Gynecology, University of Texas Medical Branch in Galveston, Galveston, Texas, USA
| | - Steve Caritis
- Departments of Obstetrics & Gynecology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Raman Venkataramanan
- Departments of Obstetrics & Gynecology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.,Department of Pharmacy, Pharmaceutical Sciences and Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - David M Haas
- Departments of Obstetrics & Gynecology, Indiana University, Indianapolis, Indiana, USA
| | - Sara K Quinney
- Departments of Obstetrics & Gynecology, Indiana University, Indianapolis, Indiana, USA
| | - Laura S Haneline
- Department of Pediatrics, Indiana University, Indianapolis, Indiana, USA
| | - Alan T Tita
- Department of Obstetrics & Gynecology, Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Tracy A Manuck
- Department of Obstetrics & Gynecology, University of North Carolina, Chapel Hill, North Carolina, USA
| | - Kenneth E Thummel
- Departments of Pharmaceutics, University of Washington, Seattle, Washington, USA
| | - Linda Morris Brown
- RTI International, Environmental, and Health Science Unit, Biostatistics and Epidemiology Division, Rockville, Maryland, USA
| | - Zhaoxia Ren
- Obstetric and Pediatric Pharmacology and Therapeutic Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, USA
| | - Zane Brown
- Department of Obstetrics & Gynecology, University of Washington, Seattle, Washington, USA
| | - Thomas R Easterling
- Department of Obstetrics & Gynecology, University of Washington, Seattle, Washington, USA.,Department of Pharmacy, University of Washington, Seattle, Washington, USA
| | - Mary F Hebert
- Department of Obstetrics & Gynecology, University of Washington, Seattle, Washington, USA.,Department of Pharmacy, University of Washington, Seattle, Washington, USA
| |
Collapse
|
6
|
Shuster DL, Shireman LM, Ma X, Shen DD, Flood Nichols SK, Ahmed MS, Clark S, Caritis S, Venkataramanan R, Haas DM, Quinney SK, Haneline LS, Tita AT, Manuck TA, Thummel KE, Morris Brown L, Ren Z, Brown Z, Easterling TR, Hebert MF. Pharmacodynamics of Metformin in Pregnant Women With Gestational Diabetes Mellitus and Nonpregnant Women With Type 2 Diabetes Mellitus. J Clin Pharmacol 2019; 60:540-549. [PMID: 31742716 DOI: 10.1002/jcph.1549] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Accepted: 10/14/2019] [Indexed: 11/07/2022]
Abstract
Gestational diabetes mellitus is a condition similar to type 2 diabetes mellitus (T2DM) in that patients are unable to compensate for the degree of insulin resistance, and both conditions are often treated with metformin. The comparative pharmacodynamic response to metformin in these 2 populations has not been studied. This study characterized insulin sensitivity, β-cell responsivity, and disposition index following a mixed-meal tolerance test utilizing a minimal model of glucose, insulin, and C-peptide kinetics before and during treatment with metformin. The study included women with gestational diabetes mellitus (n = 34), T2DM (n = 14), and healthy pregnant women (n = 30). Before treatment, the gestational diabetes mellitus group had significantly higher baseline (45%), dynamic (68%), static (71%), and total β-cell responsivity (71%) than the T2DM group. Metformin significantly increased insulin sensitivity (51%) as well as disposition index (97%) and decreased mixed-meal tolerance test peak glucose concentrations (8%) in women with gestational diabetes mellitus after adjustment for gestational age-dependent effects; however, in women with T2DM metformin only significantly affected peak glucose concentrations (22%) and had no significant effect on any other parameters. Metformin had a greater effect on the change in disposition index (Δ disposition index) in women with gestational diabetes mellitus than in those with T2DM (P = .01). In conclusion, response to metformin in women with gestational diabetes mellitus is significantly different from that in women with T2DM, which is likely related to the differences in disease severity.
Collapse
Affiliation(s)
- Diana L Shuster
- PRA Health Sciences, Clinical Pharmacology-Scientific Affairs, Lenexa, Kansas, USA
| | - Laura M Shireman
- University of Washington, Departments of Pharmaceutics, Obstetrics & Gynecology, and Pharmacy, Seattle, Washington, USA
| | - Xiaosu Ma
- Global PK/PD & Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA
| | - Danny D Shen
- University of Washington, Departments of Pharmaceutics, Obstetrics & Gynecology, and Pharmacy, Seattle, Washington, USA
| | - Shannon K Flood Nichols
- Madigan Army Medical Center, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Tacoma, Washington, USA
| | - Mahmoud S Ahmed
- University of Texas Medical Branch in Galveston, Department of Obstetrics & Gynecology, Galveston, Texas, USA
| | - Shannon Clark
- University of Texas Medical Branch in Galveston, Department of Obstetrics & Gynecology, Galveston, Texas, USA
| | - Steve Caritis
- University of Pittsburgh, Department of Obstetrics & Gynecology, Pittsburgh, Pennsylvania, USA
| | - Raman Venkataramanan
- University of Pittsburgh, Departments of Pharmacy, Pharmaceutical Sciences and Pathology, Pittsburgh, Pennsylvania, USA
| | - David M Haas
- Indiana University, Departments of Obstetrics & Gynecology and Pediatrics, Indianapolis, Indiana, USA
| | - Sara K Quinney
- Indiana University, Departments of Obstetrics & Gynecology and Pediatrics, Indianapolis, Indiana, USA
| | - Laura S Haneline
- Indiana University, Departments of Obstetrics & Gynecology and Pediatrics, Indianapolis, Indiana, USA
| | - Alan T Tita
- University of Alabama at Birmingham, Department of Obstetrics & Gynecology, Birmingham, Alabama, USA
| | - Tracy A Manuck
- University of North Carolina, Department of Obstetrics & Gynecology, Chapel Hill, North Carolina, USA
| | - Kenneth E Thummel
- University of Washington, Departments of Pharmaceutics, Obstetrics & Gynecology, and Pharmacy, Seattle, Washington, USA
| | - Linda Morris Brown
- RTI International, Environmental and Health Science Unit, Biostatistics and Epidemiology Division, Rockville, Maryland, USA
| | - Zhaoxia Ren
- Obstetric and Pediatric Pharmacology and Therapeutic Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, USA
| | - Zane Brown
- University of Washington, Departments of Pharmaceutics, Obstetrics & Gynecology, and Pharmacy, Seattle, Washington, USA
| | - Thomas R Easterling
- University of Washington, Departments of Pharmaceutics, Obstetrics & Gynecology, and Pharmacy, Seattle, Washington, USA
| | - Mary F Hebert
- University of Washington, Departments of Pharmaceutics, Obstetrics & Gynecology, and Pharmacy, Seattle, Washington, USA
| |
Collapse
|
7
|
Leung DH, Wirth S, Yao BB, Viani RM, Gonzalez‐Peralta RP, Jonas MM, Lobritto SJ, Narkewicz MR, Sokal E, Fortuny C, Hsu EK, Del Valle‐Segarra A, Zha J, Larsen L, Liu L, Shuster DL, Cohen DE, Rosenthal P. Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4. Hepatol Commun 2018; 2:1311-1319. [PMID: 30411078 PMCID: PMC6211326 DOI: 10.1002/hep4.1250] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Accepted: 07/31/2018] [Indexed: 12/12/2022] Open
Abstract
In adults, treatment of hepatitis C virus (HCV) infection with ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) with or without dasabuvir (DSV) and ±ribavirin (RBV) results in high rates of sustained virologic response (SVR). However, these regimens have not been investigated in adolescents. This ongoing, open-label, phase 2/3 study evaluated the pharmacokinetics, safety, and efficacy of OBV/PTV/r+DSV±RBV treatment for 12 weeks in adolescents infected with HCV genotype (GT) 1 without cirrhosis (part 1) and the safety and efficacy of OBV/PTV/r±DSV±RBV treatment for 12 or 24 weeks in adolescents infected with GT1 or GT4 without cirrhosis or with compensated cirrhosis (parts 1 and 2). Patients were 12-17 years of age and treatment naive or interferon experienced. Treatment regimens were based on HCV GT and cirrhosis status. Endpoints were SVR at posttreatment week 12 (SVR12), adverse events (AEs), and pharmacokinetic parameters. Thirty-eight adolescents were enrolled, 66% were female patients, and 76% were White; 42%, 40%, and 18% of patients had HCV GT1a, GT1b, and GT4 infections, respectively. Median age was 15 years (range, 12-17 years), and 1 patient had cirrhosis. The SVR12 rate was 100% (38/38; 95% confidence interval [CI], 90.8%-100%). No treatment-emergent grade 3 or 4 laboratory abnormalities were reported. No serious AEs occurred on treatment, and no AEs led to study drug discontinuation. The most common AEs were headache (21%), fatigue (18%), nasopharyngitis (13%), pruritus (13%), and upper respiratory tract infection (11%). Intensive pharmacokinetic results showed OBV, PTV, DSV, and ritonavir drug exposures were comparable to those seen in adults. Conclusion: Treatment with OBV/PTV/r±DSV±RBV was well tolerated and highly efficacious in adolescents with HCV GT1 or GT4 infection.
Collapse
Affiliation(s)
- Daniel H. Leung
- Division of Gastroenterology, Hepatology, and Nutrition, Texas Children’s Hospital and Department of PediatricsBaylor College of MedicineHoustonTX
| | - Stefan Wirth
- HELIOS Medical Center Wuppertal, Department of PediatricsWitten/Herdecke UniversityWuppertalGermany
| | | | - Rolando M. Viani
- AbbVie IncNorth ChicagoIL
- Present address:
University of California San DiegoSchool of MedicineSan DiegoCA
| | - Regino P. Gonzalez‐Peralta
- Department of PediatricsUniversity of Florida College of Medicine and Shands Children’s HospitalGainesvilleFL
- Present address:
Division of GastroenterologyHepatology and Liver TransplantationFlorida Hospital for ChildrenOrlandoFL
| | - Maureen M. Jonas
- Division of Gastroenterology, Hepatology, and Nutrition, Boston Children’s Hospital and Department of PediatricsHarvard Medical SchoolBostonMA
| | - Steven J. Lobritto
- New York‐Presbyterian Morgan Stanley Children’s HospitalDepartment of PediatricsColumbia University Medical CenterNew YorkNY
| | - Michael R. Narkewicz
- Digestive Health InstituteChildren’s Hospital Colorado and Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of PediatricsUniversity of Colorado School of MedicineAuroraCO
| | - Etienne Sokal
- Cliniques Universitaires Saint‐Luc, Université Catholique de LouvainBrusselsBelgium
| | - Clàudia Fortuny
- Servei de PediatriaHospital Sant Joan de Déu y Universitat de BarcelonaBarcelonaSpain
| | - Evelyn K. Hsu
- Seattle Children’s Hospital and Department of PediatricsUniversity of Washington School of MedicineSeattleWA
| | | | | | | | - Li Liu
- AbbVie IncNorth ChicagoIL
| | - Diana L. Shuster
- AbbVie IncNorth ChicagoIL
- Present address:
PRA Health SciencesRaleighNC
| | | | - Philip Rosenthal
- Department of PediatricsUniversity of California San FranciscoSan FranciscoCA
| |
Collapse
|
8
|
Bernstein DE, Tran A, Martin P, Kowdley KV, Bourliere M, Sulkowski MS, Pockros PJ, Renjifo B, Wang D, Shuster DL, Cohen DE, Jacobson IM. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease. Kidney Int Rep 2018; 4:245-256. [PMID: 30775621 PMCID: PMC6365509 DOI: 10.1016/j.ekir.2018.10.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2018] [Accepted: 10/08/2018] [Indexed: 12/23/2022] Open
Abstract
Introduction Patients with hepatitis C virus (HCV) infection and chronic kidney disease (CKD) are a high-priority population for treatment. Methods We performed a post hoc pooled efficacy and safety analysis that included HCV genotype 1–infected patients with compensated liver disease and CKD stages 1 to 3 who received the all-oral 3–direct-acting antiviral regimen of ombitasvir, paritaprevir, ritonavir, and dasabuvir ± ribavirin (OBV/PTV/r + DSV ± RBV) in 11 phase 3 clinical trials. Sustained virologic response rates at posttreatment week 12 (SVR12) and treatment-related adverse events (AEs), serious AEs, and renal-associated AEs are reported. Mean changes from baseline in serum creatinine and estimated glomerular filtration rate (eGFR) were calculated to assess changes in renal function. Factors associated with improved eGFR were assessed by stepwise logistic regression analysis of data from 7 trials in which baseline urinalysis was collected. Results SVR12 rates in patients with stage 1, 2, and 3 CKD were 97% (439/453), 98% (536/547), and 97% (32/33), respectively, with OBV/PTV/r + DSV; and, 96% (1172/1221), 96% (1208/1254), and 93% (55/59), respectively, with OBV/PTV/r + DSV + RBV. Overall rates of serious AEs and renal AEs were 3% (95/3567) and 2% (56/3567), respectively. Factors associated with an eGFR increase of ≥10 ml/min per 1.73 m2 were baseline proteinuria, body mass index, nonblack race, and history of diabetes. Conclusion OBV/PTV/r + DSV ± RBV achieved high SVR rates and was generally well tolerated irrespective of CKD stage.
Collapse
Affiliation(s)
- David E Bernstein
- Division of Hepatology, Hofstra Northwell School of Medicine, Manhasset, New York, USA
| | - Albert Tran
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1065, Team 8, "Hepatic Complications in Obesity," Nice, F-06204, Cedex 3, France and University Hospital of Nice, Digestive Centre, Nice, F-06202, Cedex 3, France
| | - Paul Martin
- Division of Hepatology, School of Medicine, University of Miami, Miami, Florida, USA
| | | | | | - Mark S Sulkowski
- Viral Hepatitis Center, Johns Hopkins University, Baltimore, Maryland, USA
| | - Paul J Pockros
- Division of Gastroenterology/Hepatology, Scripps Clinic, La Jolla, California, USA
| | | | - Deli Wang
- AbbVie Inc., North Chicago, Illinois, USA
| | | | | | | |
Collapse
|
9
|
Shuster DL, Menon RM, Ding B, Khatri A, Li H, Cohen E, Jewett M, Cohen DE, Zha J. Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials. Eur J Clin Pharmacol 2018; 75:207-216. [PMID: 30291369 DOI: 10.1007/s00228-018-2566-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Accepted: 09/25/2018] [Indexed: 01/20/2023]
Abstract
PURPOSE To characterize the pharmacokinetics of ombitasvir, paritaprevir, ritonavir, dasabuvir, and ribavirin in hepatitis C virus (HCV)-infected patients with chronic kidney disease stage 4 (CKD4) or end-stage renal disease (ESRD), including those on dialysis, in the open-label phase 3 RUBY-I and RUBY-II studies. METHODS Patients (n = 18 CKD4, n = 68 ESRD) received ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily ± dasabuvir 250 mg twice daily ± ribavirin 200 mg once daily for 12 or 24 weeks. Intensive pharmacokinetic samples were collected from ten patients; sparse samples were collected from all patients. Arterial and venous samples were collected from three patients during hemodialysis. Area under the plasma concentration-time curve (AUC) was estimated using noncompartmental analyses for intensive data, and steady-state trough concentrations (Ctrough) were obtained from the sparse data. Pharmacokinetic results from RUBY-I and RUBY-II were compared empirically to historical data. RESULTS The AUC values of ombitasvir, paritaprevir, ritonavir, and dasabuvir were comparable between CKD4 and ESRD patients and were within the range of values observed in historical studies; dialysis had no effect on drug exposures. Ribavirin was extracted during hemodialysis but had similar exposures on dialysis and non-dialysis days. Individual steady-state Ctrough values for each drug overlapped between CKD4 and ESRD patients, and values in both groups were similar to historical values. CONCLUSION Plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir were not altered by renal impairment or dialysis, suggesting these agents can be administered to HCV-infected CKD4 or ESRD patients, including those on dialysis, without dose adjustment. TRIAL REGISTRATION Clinicaltrials.gov identifiers: NCT02207088 (RUBY-I) and NCT02487199 (RUBY-II).
Collapse
Affiliation(s)
- Diana L Shuster
- Clinical Pharmacology and Pharmacometrics, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA
| | - Rajeev M Menon
- Clinical Pharmacology and Pharmacometrics, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA
| | - Bifeng Ding
- Clinical Pharmacology and Pharmacometrics, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA
| | - Amit Khatri
- Clinical Pharmacology and Pharmacometrics, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA
| | - Hong Li
- Clinical Pharmacology and Pharmacometrics, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA
| | - Eric Cohen
- Clinical Pharmacology and Pharmacometrics, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA
| | - Melissa Jewett
- Clinical Pharmacology and Pharmacometrics, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA
| | - Daniel E Cohen
- Clinical Pharmacology and Pharmacometrics, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA
| | - Jiuhong Zha
- Clinical Pharmacology and Pharmacometrics, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA.
| |
Collapse
|
10
|
Abstract
Ombitasvir is a potent, nonstructural protein 5A inhibitor of the hepatitis C virus (HCV) that is used in combination with other direct-acting antivirals for the treatment of chronic HCV infection. Ombitasvir is predominantly metabolized by amide hydrolysis followed by oxidative metabolism and is a substrate of P-glycoprotein. Ombitasvir displays linear pharmacokinetics with minimal accumulation and is eliminated via metabolism and biliary excretion. A negligible amount of unchanged drug is excreted in urine. Exposures are comparable across Chinese, Japanese, and non-Asian subjects. The pharmacokinetic characteristics of ombitasvir are similar in healthy subjects and HCV-infected patients, and are not appreciably altered by hepatic or renal impairment. Results from several drug interaction studies demonstrated that ombitasvir has a low potential for drug interactions.
Collapse
Affiliation(s)
- Prajakta S Badri
- Clinical Pharmacology and Pharmacometrics, AbbVie Inc., Dept. R4PK, Bldg. AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064, USA
| | - Diana L Shuster
- Clinical Pharmacology and Pharmacometrics, AbbVie Inc., Dept. R4PK, Bldg. AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064, USA
| | - Sandeep Dutta
- Clinical Pharmacology and Pharmacometrics, AbbVie Inc., Dept. R4PK, Bldg. AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064, USA
| | - Rajeev M Menon
- Clinical Pharmacology and Pharmacometrics, AbbVie Inc., Dept. R4PK, Bldg. AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064, USA.
| |
Collapse
|
11
|
Vyhlidal CA, Pearce RE, Gaedigk R, Calamia JC, Shuster DL, Thummel KE, Leeder JS. Variability in Expression of CYP3A5 in Human Fetal Liver. Drug Metab Dispos 2015; 43:1286-93. [PMID: 25979262 DOI: 10.1124/dmd.115.064998] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Accepted: 05/15/2015] [Indexed: 01/27/2023] Open
Abstract
Members of the cytochrome P450 3A (CYP3A) subfamily of drug metabolizing enzymes exhibit developmental changes in expression in human liver characterized by a transition between CYP3A7 and CYP3A4 over the first few years of life. In contrast, the developmental expression of CYP3A5 is less well understood due to polymorphic expression of the enzyme in human tissues as a result of the prevalence of the CYP3A5*3 allele, which leads to alternative splicing. We further explored the expression of CYP3A5 and the impact of alternative splicing on the variability of CYP3A5 functional activity in a large bank of human prenatal liver samples (7 to 32 weeks of age postconception). The expression of normally spliced CYP3A5 mRNA in all human fetal liver samples varied 235-fold whereas CYP3A5 SV1 mRNA was only detected in fetal liver samples with at least one CYP3A5*3 allele. Formation of 1'-OH midazolam (MDZ) varied 79-fold, and the ratio of 1'-OH MDZ to 4-OH MDZ varied 8-fold and depended on the presence or absence of the CYP3A5*3 allele. Formation of 4-OH MDZ was significantly associated with 1'-OH MDZ (r(2) = 0.76, P < 0.0001) but varied (36-fold) independently of CYP3A5 genotype or expression. The substantial interindividual variability that remains even after stratification for CYP3A5 genotype suggests that factors such as environmental exposure and epigenetic alterations act in addition to genetic variation to contribute to the variability of CYP3A5 expression in human prenatal liver.
Collapse
Affiliation(s)
- Carrie A Vyhlidal
- Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri (C.A.V., R.E.P., R.G., J.S.L.); Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (J.C.C., D.L.S., K.E.T.)
| | - Robin E Pearce
- Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri (C.A.V., R.E.P., R.G., J.S.L.); Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (J.C.C., D.L.S., K.E.T.)
| | - Roger Gaedigk
- Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri (C.A.V., R.E.P., R.G., J.S.L.); Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (J.C.C., D.L.S., K.E.T.)
| | - Justina C Calamia
- Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri (C.A.V., R.E.P., R.G., J.S.L.); Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (J.C.C., D.L.S., K.E.T.)
| | - Diana L Shuster
- Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri (C.A.V., R.E.P., R.G., J.S.L.); Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (J.C.C., D.L.S., K.E.T.)
| | - Kenneth E Thummel
- Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri (C.A.V., R.E.P., R.G., J.S.L.); Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (J.C.C., D.L.S., K.E.T.)
| | - J Steven Leeder
- Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri (C.A.V., R.E.P., R.G., J.S.L.); Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (J.C.C., D.L.S., K.E.T.)
| |
Collapse
|
12
|
Shuster DL, Risler LJ, Prasad B, Calamia JC, Voellinger JL, Kelly EJ, Unadkat JD, Hebert MF, Shen DD, Thummel KE, Mao Q. Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochem Pharmacol 2014; 92:690-700. [PMID: 25450675 DOI: 10.1016/j.bcp.2014.09.025] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2014] [Revised: 09/02/2014] [Accepted: 09/29/2014] [Indexed: 02/04/2023]
Abstract
Glyburide is commonly prescribed for the treatment of gestational diabetes mellitus; however, fetal exposure to glyburide is not well understood and may have short- and long-term consequences for the health of the child. Glyburide can cross the placenta; fetal concentrations at term are nearly comparable to maternal levels. Whether or not glyburide is metabolized in the fetus and by what mechanisms has yet to be determined. In this study, we determined the kinetic parameters for glyburide depletion by CYP3A isoenzymes; characterized glyburide metabolism by human fetal liver tissues collected during the first or early second trimester of pregnancy; and identified the major enzyme responsible for glyburide metabolism in human fetal livers. CYP3A4 had the highest metabolic capacity towards glyburide, followed by CYP3A7 and CYP3A5 (Clint,u=37.1, 13.0, and 8.7ml/min/nmol P450, respectively). M5 was the predominant metabolite generated by CYP3A7 and human fetal liver microsomes (HFLMs) with approximately 96% relative abundance. M5 was also the dominant metabolite generated by CYP3A4, CYP3A5, and adult liver microsomes; however, M1-M4 were also present, with up to 15% relative abundance. CYP3A7 protein levels in HFLMs were highly correlated with glyburide Clint, 16α-OH DHEA formation, and 4'-OH midazolam formation. Likewise, glyburide Clint was highly correlated with 16α-OH DHEA formation. Fetal demographics as well as CYP3A5 and CYP3A7 genotype did not alter CYP3A7 protein levels or glyburide Clint. These results indicate that human fetal livers metabolize glyburide predominantly to M5 and that CYP3A7 is the major enzyme responsible for glyburide metabolism in human fetal livers.
Collapse
Affiliation(s)
- Diana L Shuster
- Department of Pharmaceutics, School of Pharmacy, University of Washington, Box 357610, Seattle, WA 98195, USA.
| | - Linda J Risler
- Department of Pharmacy, University of Washington, Box 357630, Seattle, Washington 98195, USA.
| | - Bhagwat Prasad
- Department of Pharmaceutics, School of Pharmacy, University of Washington, Box 357610, Seattle, WA 98195, USA.
| | - Justina C Calamia
- Department of Pharmaceutics, School of Pharmacy, University of Washington, Box 357610, Seattle, WA 98195, USA.
| | - Jenna L Voellinger
- Department of Pharmaceutics, School of Pharmacy, University of Washington, Box 357610, Seattle, WA 98195, USA.
| | - Edward J Kelly
- Department of Pharmaceutics, School of Pharmacy, University of Washington, Box 357610, Seattle, WA 98195, USA.
| | - Jashvant D Unadkat
- Department of Pharmaceutics, School of Pharmacy, University of Washington, Box 357610, Seattle, WA 98195, USA.
| | - Mary F Hebert
- Department of Pharmacy, University of Washington, Box 357630, Seattle, Washington 98195, USA; Department of Obstetrics and Gynecology, University of Washington, Box 356460, Seattle, Washington 98195, USA.
| | - Danny D Shen
- Department of Pharmaceutics, School of Pharmacy, University of Washington, Box 357610, Seattle, WA 98195, USA; Department of Pharmacy, University of Washington, Box 357630, Seattle, Washington 98195, USA.
| | - Kenneth E Thummel
- Department of Pharmaceutics, School of Pharmacy, University of Washington, Box 357610, Seattle, WA 98195, USA.
| | - Qingcheng Mao
- Department of Pharmaceutics, School of Pharmacy, University of Washington, Box 357610, Seattle, WA 98195, USA.
| |
Collapse
|
13
|
Shuster DL, Risler LJ, Liang CKJ, Rice KM, Shen DD, Hebert MF, Thummel KE, Mao Q. Maternal-fetal disposition of glyburide in pregnant mice is dependent on gestational age. J Pharmacol Exp Ther 2014; 350:425-34. [PMID: 24898265 DOI: 10.1124/jpet.114.213470] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Gestational diabetes mellitus is a major complication of human pregnancy. The oral clearance (CL) of glyburide, an oral antidiabetic drug, increases 2-fold in pregnant women during late gestation versus nonpregnant controls. In this study, we examined gestational age-dependent changes in maternal-fetal pharmacokinetics (PK) of glyburide and metabolites in a pregnant mouse model. Nonpregnant and pregnant FVB mice were given glyburide by retro-orbital injection. Maternal plasma was collected over 240 minutes on gestation days (gd) 0, 7.5, 10, 15, and 19; fetuses were collected on gd 15 and 19. Glyburide and metabolites were quantified using high-performance liquid chromatography-mass spectrometry, and PK analyses were performed using a pooled data bootstrap approach. Maternal CL of glyburide increased approximately 2-fold on gd 10, 15, and 19 compared with nonpregnant controls. Intrinsic CL of glyburide in maternal liver microsomes also increased as gestation progressed. Maternal metabolite/glyburide area under the curve ratios were generally unchanged or slightly decreased throughout gestation. Total fetal exposure to glyburide was <5% of maternal plasma exposure, and was doubled on gd 19 versus gd 15. Fetal metabolite concentrations were below the limit of assay detection. This is the first evidence of gestational age-dependent changes in glyburide PK. Increased maternal glyburide clearance during gestation is attributable to increased hepatic metabolism. Metabolite elimination may also increase during pregnancy. In the mouse model, fetal exposure to glyburide is gestational age-dependent and low compared with maternal plasma exposure. These results indicate that maternal glyburide therapeutic strategies may require adjustments in a gestational age-dependent manner if these same changes occur in humans.
Collapse
Affiliation(s)
- Diana L Shuster
- Departments of Pharmaceutics (D.L.S., L.J.R., D.D.S., K.E.T., Q.M.) and Pharmacy (D.D.S., M.F.H.), School of Pharmacy, University of Washington, Seattle, Washington; Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington (C.-K.J.L., K.M.R.); and Department of Obstetrics and Gynecology, School of Medicine (M.F.H.), University of Washington, Seattle, Washington
| | - Linda J Risler
- Departments of Pharmaceutics (D.L.S., L.J.R., D.D.S., K.E.T., Q.M.) and Pharmacy (D.D.S., M.F.H.), School of Pharmacy, University of Washington, Seattle, Washington; Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington (C.-K.J.L., K.M.R.); and Department of Obstetrics and Gynecology, School of Medicine (M.F.H.), University of Washington, Seattle, Washington
| | - Chao-Kang J Liang
- Departments of Pharmaceutics (D.L.S., L.J.R., D.D.S., K.E.T., Q.M.) and Pharmacy (D.D.S., M.F.H.), School of Pharmacy, University of Washington, Seattle, Washington; Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington (C.-K.J.L., K.M.R.); and Department of Obstetrics and Gynecology, School of Medicine (M.F.H.), University of Washington, Seattle, Washington
| | - Kenneth M Rice
- Departments of Pharmaceutics (D.L.S., L.J.R., D.D.S., K.E.T., Q.M.) and Pharmacy (D.D.S., M.F.H.), School of Pharmacy, University of Washington, Seattle, Washington; Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington (C.-K.J.L., K.M.R.); and Department of Obstetrics and Gynecology, School of Medicine (M.F.H.), University of Washington, Seattle, Washington
| | - Danny D Shen
- Departments of Pharmaceutics (D.L.S., L.J.R., D.D.S., K.E.T., Q.M.) and Pharmacy (D.D.S., M.F.H.), School of Pharmacy, University of Washington, Seattle, Washington; Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington (C.-K.J.L., K.M.R.); and Department of Obstetrics and Gynecology, School of Medicine (M.F.H.), University of Washington, Seattle, Washington
| | - Mary F Hebert
- Departments of Pharmaceutics (D.L.S., L.J.R., D.D.S., K.E.T., Q.M.) and Pharmacy (D.D.S., M.F.H.), School of Pharmacy, University of Washington, Seattle, Washington; Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington (C.-K.J.L., K.M.R.); and Department of Obstetrics and Gynecology, School of Medicine (M.F.H.), University of Washington, Seattle, Washington
| | - Kenneth E Thummel
- Departments of Pharmaceutics (D.L.S., L.J.R., D.D.S., K.E.T., Q.M.) and Pharmacy (D.D.S., M.F.H.), School of Pharmacy, University of Washington, Seattle, Washington; Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington (C.-K.J.L., K.M.R.); and Department of Obstetrics and Gynecology, School of Medicine (M.F.H.), University of Washington, Seattle, Washington
| | - Qingcheng Mao
- Departments of Pharmaceutics (D.L.S., L.J.R., D.D.S., K.E.T., Q.M.) and Pharmacy (D.D.S., M.F.H.), School of Pharmacy, University of Washington, Seattle, Washington; Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington (C.-K.J.L., K.M.R.); and Department of Obstetrics and Gynecology, School of Medicine (M.F.H.), University of Washington, Seattle, Washington
| |
Collapse
|
14
|
Shuster DL, Bammler TK, Beyer RP, Macdonald JW, Tsai JM, Farin FM, Hebert MF, Thummel KE, Mao Q. Gestational age-dependent changes in gene expression of metabolic enzymes and transporters in pregnant mice. Drug Metab Dispos 2012; 41:332-42. [PMID: 23175668 DOI: 10.1124/dmd.112.049718] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Pregnancy-induced changes in drug pharmacokinetics can be explained by changes in expression of drug-metabolizing enzymes and transporters and/or normal physiology. In this study, we determined gestational age-dependent expression profiles for all metabolic enzyme and transporter genes in the maternal liver, kidney, small intestine, and placenta of pregnant mice by microarray analysis. We specifically examined the expression of genes important for xenobiotic, bile acid, and steroid hormone metabolism and disposition, namely, cytochrome P450s (Cyp), UDP-glucuronosyltranserases (Ugt), sulfotransferases (Sult), and ATP-binding cassette (Abc), solute carrier (Slc), and solute carrier organic anion (Slco) transporters. Few Ugt and Sult genes were affected by pregnancy. Cyp17a1 expression in the maternal liver increased 3- to 10-fold during pregnancy, which was the largest observed change in the maternal tissues. Cyp1a2, most Cyp2 isoforms, Cyp3a11, and Cyp3a13 expression in the liver decreased on gestation days (gd) 15 and 19 compared with nonpregnant controls (gd 0). In contrast, Cyp2d40, Cyp3a16, Cyp3a41a, Cyp3a41b, and Cyp3a44 in the liver were induced throughout pregnancy. In the placenta, Cyp expression on gd 10 and 15 was upregulated compared with gd 19. Notable changes were also observed in Abc and Slc transporters. Abcc3 expression in the liver and Abcb1a, Abcc4, and Slco4c1 expression in the kidney were downregulated on gd 15 and 19. In the placenta, Slc22a3 (Oct3) expression on gd 10 was 90% lower than that on gd 15 and 19. This study demonstrates important gestational age-dependent expression of metabolic enzyme and transporter genes, which may have mechanistic relevance to drug disposition in human pregnancy.
Collapse
Affiliation(s)
- Diana L Shuster
- Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA 98195-7610, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Ni Z, Bikadi Z, Shuster DL, Zhao C, Rosenberg MF, Mao Q. Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity. Biochemistry 2011; 50:8057-66. [PMID: 21854076 DOI: 10.1021/bi200573t] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The human breast cancer resistance protein (BCRP/ABCG2) confers multidrug resistance and mediates the active efflux of drugs and xenobiotics. BCRP contains one nucleotide-binding domain (NBD) followed by one membrane-spanning domain (MSD). We investigated whether prolines in or near the transmembrane helices are essential for BCRP function. Six proline residues were substituted with alanine individually, and the mutants were stably expressed in Flp-In(TM)-293 cells at levels comparable to that of wild-type BCRP and predominantly localized on the plasma membrane of the cells. While P392A showed a significant reduction (35-50%) in the efflux activity of mitoxantrone, BODIPY-prazosin, and Hoechst 33342, P485A exhibited a significant decrease of approximately 70% in the efflux activity of only BODIPY-prazosin. Other mutants had no significant changes in the efflux activities of these substrates. Drug resistance profiles of the cells expressing the mutants correlated well with the efflux data. ATPase activity was not substantially affected for P392A or P485A compared to that of wild-type BCRP. These results strongly suggest Pro(392) and Pro(485) are important in determining the overall transport activity and substrate selectivity of BCRP, respectively. Prazosin differentially affected the binding of 5D3, a conformation-sensitive antibody, to wild-type BCRP, P392A, or P485A in a concentration-dependent manner. In contrast, mitoxantrone had no significant effect on 5D3 binding. Homology modeling indicates that Pro(392) may play an important role in the communication between the MSD and NBD as it is predicted to be located at the interface between the two functional domains, and Pro(485) induces flexible hinges that may be essential for the broad substrate specificity of BCRP.
Collapse
Affiliation(s)
- Zhanglin Ni
- Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington 98195-7610, USA
| | | | | | | | | | | |
Collapse
|
16
|
Chang SD, Steinberg GK, Levy RP, Marks MP, Frankel KA, Shuster DL, Marcellus ML. Microsurgical resection of incompletely obliterated intracranial arteriovenous malformations following stereotactic radiosurgery. Neurol Med Chir (Tokyo) 1999; 38 Suppl:200-7. [PMID: 10235006 DOI: 10.2176/nmc.38.suppl_200] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Radiosurgery is effective in obliterating small arteriovenous malformations (AVMs), but less successful in thrombosing larger AVMs. This study reviewed patients who underwent surgical resection of their large AVMs following failed radiosurgical obliteration. AVMs from 36 patients (aged 7 to 64 years, mean 29.9) were surgically resected 1 to 11 years after radiosurgery. Initial AVM volumes were 0.7 to 117 cm3 (mean 21.6 cm3), and radiosurgical doses ranged from 4.6 to 45 Gray equivalent (GyE) (mean 21.1 GyE). Thirty AVMs (83%) were located in eloquent tissue. Venous drainage was deep (14), superficial (13), or both (9). Spetzler grades were II (2), III (12), IV (18), and V (4). Nine patients suffered rehemorrhage after radiosurgery but prior to surgery, while three patients developed radiation necrosis. Twenty-seven patients underwent endovascular embolization prior to surgery. During microsurgical resection, the AVMs were found to be significantly less vascular and more easily resected, compared to AVMs in patients who had not received radiosurgery. Histology showed endothelial proliferation with hyaline and mineralization in vessel walls. Partial or complete thrombosis of some AVM vessels, and evidence of vessel and brain necrosis were noted in many cases. Clinical outcome was excellent or good in 34 cases, with two patients dying of rebleeding from residual AVM. Five patients were neurologically worse following microsurgical resection. Final outcome was largely related to the pretreatment grade. Radiosurgery several years prior to surgical resection appears useful in treating unusually large and complex AVMs.
Collapse
Affiliation(s)
- S D Chang
- Department of Neurosurgery, Stanford University School of Medicine, California, USA
| | | | | | | | | | | | | |
Collapse
|
17
|
Horoupian DS, Shuster DL, Kaarsoo-Herrick M, Shuer LM. Central neurocytoma: one associated with a fourth ventricular PNET/medulloblastoma and the second mixed with adipose tissue. Hum Pathol 1997; 28:1111-4. [PMID: 9308737 DOI: 10.1016/s0046-8177(97)90066-6] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We report two cases of central neurocytoma; one located in the right lateral ventricle and associated with a distinctly separate primitive neuroectodermal tumor (PNET)/medulloblastoma of the fourth ventricle, and the other admixed with fat cells and arising from the left lateral and third ventricles with extension into the corpus callosum. We discuss that concurrent occurrences of PNET and adipose tissue are not fortuitous events, but an evidence that neurocytomas and PNETs originate in the residual germinal pool from common progenitor cell rests recapitulating features of developing neurons and with a potential for mesenchymal differentiation.
Collapse
Affiliation(s)
- D S Horoupian
- Department of Pathology (Neuropathology), Stanford University, CA 94305, USA
| | | | | | | |
Collapse
|
18
|
Chang SD, Shuster DL, Steinberg GK, Levy RP, Frankel K. Stereotactic radiosurgery of arteriovenous malformations: pathologic changes in resected tissue. Clin Neuropathol 1997; 16:111-6. [PMID: 9101115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Both stereotactic radiosurgery and microsurgery are treatment modalities for arteriovenous malformations (AVM), and more recently, multimodality treatment using these approaches has been utilized. We surgically resected AVMs from 33 patients (ages 7-64 years old, mean age 30.4) 1-11 years after radiosurgery. AVM volumes were 0.8-117 cm3 (mean 21.6 cm3), and doses ranged from 4.6-45 GyE (mean 21.2 GyE). AVMs resected were submitted for pathologic review. Each AVM was evaluated for the following radiation changes, and the number of AVMs demonstrating these changes were noted: endothelial proliferation (27), hyaline (18) and calcium (10) in AVM vessel walls, partial (9) or complete (24) thrombosis of some AVM vessels, and necrosis of vessels (15) and adjacent brain tissue (11). A semiquantitative scale (mild, moderate, severe) incorporating the aforementioned changes present in each case classified the extent of radiation-induced change. There was a significant correlation (r = 0.624, p < 0.01) between extent of radiation change and dose of radiation received. There was no absolute radiation dose threshold below which radiation-induced changes were absent. However, all but one patient receiving greater than 20 GyE developed moderate to severe radiation vascular changes and the 3 patients treated with greater than 30 GyE all had severe radiation-induced changes. Radiation changes in AVMs following stereotactic radiosurgery appear to be dose-related. The correlation of dose to extent of radiation change may allow the determination of the optimal dose of radiation to treat AVMs.
Collapse
Affiliation(s)
- S D Chang
- Department of Neurosurgery, Stanford University School of Medicine, California, USA
| | | | | | | | | |
Collapse
|